研報掘金丨浙商證券:予愷英網絡“買入”評級,看好公司未來產品線
浙商證券研報指出,愷英網絡(002517.SZ)回購並註銷提振投資者信心。公司產品線儲備豐富,有《斗羅大陸:誅邪傳説》《納薩力克:崛起》《三國:天下歸心》《代號:X》《代號:傳説》《代號:BLEACH》《王者傳奇2》《蒸汽堡壘》《數碼寶貝:源碼》等多個品類的遊戲在研,其中,《盜墓筆記:啟程》和《代號:鬥羅》作為知名IP,受到關注度較高。同時,公司持續發力海外市場,已初步建立起一套海外發行策略,積極佈局歐美市場地區。看好公司未來產品線,並認為此次註銷回購的股份有望提振投資者信心,對公司估值水平有一定正向促進作用,給予“買入”評級。
Follow us
Find us on
Facebook,
Twitter ,
Instagram, and
YouTube or frequent updates on all things investing.Have a financial topic you would like to discuss? Head over to the
uSMART Community to share your thoughts and insights about the market! Click the picture below to download and explore uSMART app!

Disclaimers
uSmart Securities Limited (“uSmart”) is based on its internal research and public third party information in preparation of this article. Although uSmart uses its best endeavours to ensure the content of this article is accurate, uSmart does not guarantee the accuracy, timeliness or completeness of the information of this article and is not responsible for any views/opinions/comments in this article. Opinions, forecasts and estimations reflect uSmart’s assessment as of the date of this article and are subject to change. uSmart has no obligation to notify you or anyone of any such changes. You must make independent analysis and judgment on any matters involved in this article. uSmart and any directors, officers, employees or agents of uSmart will not be liable for any loss or damage suffered by any person in reliance on any representation or omission in the content of this article. The content of the article is for reference only and does not constitute any offer, solicitation, recommendation, opinion or guarantee of any securities, virtual assets, financial products or instruments. Regulatory authorities may restrict the trading of virtual asset-related ETFs to only investors who meet specified requirements. Any calculations or images in the article are for illustrative purposes only.
Investment involves risks and the value and income from securities may rise or fall. Past performance is not indicative of future performance. Please carefully consider your personal risk tolerance, and consult independent professional advice if necessary.